#United States #Southlake #Oppenheimer #Renibus Therapeutics #RBT-1

Renibus Therapeutics at the Oppenheimer Private Life Sciences Showcase

Renibus Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in the Oppenheimer Private Life Sciences Showcase scheduled for September 29, 2026. This annual event serves as a platform for innovative companies in the life sciences sector to present their advancements to potential investors and industry stakeholders, offering a glimpse into the future of healthcare innovations.

Event Participation Details

Bhupinder Singh, MD, FASN, FNKF, the Chief Medical Officer of Renibus, is set to deliver a virtual presentation at 11:15 AM Eastern Standard Time on the day of the event. In addition to the presentation, the company management is also planning to engage in one-on-one meetings with investors, offering them insights into Renibus' current projects and future plans.

Focus on Cardiac and Renal Health

Renibus Therapeutics operates at the forefront of developing treatments for cardio-renal and metabolic diseases. The company’s flagship drug, Veverimer, is currently in Phase 3 trials targeting metabolic acidosis in adults with chronic kidney disease. This innovative treatment aims to improve patient outcomes and reduce the burden of chronic conditions affecting kidney health.

Moreover, Renibus is progressing with its second late-stage program, RBT-1, designed for patients undergoing cardiac surgery. Recently, this program completed the PROTECT Phase 3 trial. Initial results show promise, indicating that RBT-1 may further benefit patients identified as at risk post-surgery. The potential for advancing this program into wider clinical use is currently under evaluation.

Recognizing the urgency and need in this field, RBT-1 has earned both Breakthrough Therapy and Fast Track designations from the FDA, reflecting its significance within the treatment landscape.

Company Overview

Founded with a mission to enhance patient care through highly-targeted therapies, Renibus Therapeutics leverages scientific expertise to bridge gaps in existing treatments for heart and kidney-related conditions. The focus on prevention and treatment underscores a commitment not only to innovation but also to a broader understanding of patient needs in managing chronic diseases.

For more information about Renibus Therapeutics, their ongoing projects, and participation in the Oppenheimer Showcase, interested parties can visit their official website at www.Renibus.com.

Conclusion

As Renibus gears up for a significant presence at the Oppenheimer Private Life Sciences Showcase, stakeholders around the healthcare landscape await insights from their innovative projects. The event promises to highlight the critical developments made by Renibus Therapeutics as they continue to advocate for better health outcomes in patients facing cardio-renal and metabolic diseases. This participation not only enhances their visibility among investors but also signifies their ongoing commitment to advancing medical science for patients in need.